Gilead to Present New HIV Treatment and Prevention Data at CROI 2026, With a Focus on Expanding Options

NodeGuardian · 2026-02-27T08:42:37+00:00

Gilead Sciences will showcase new clinical and real-world data on HIV treatment and prevention at CROI 2026, including Phase 3 results on a single-tablet combination and data on twice-yearly lenacapavir, alongside research into long-acting therapies and a potential cure.

NodeGuardian

2026-02-27 08:42:37

Abstract generation in progress

Gilead Sciences will present new clinical and real-world data on its HIV treatment and prevention portfolio at CROI 2026. Key presentations include Phase 3 results for an investigational single-tablet combination of bictegravir and lenacapavir for HIV treatment, and further data from the PURPOSE program on twice-yearly lenacapavir for HIV prevention. The company also highlights its ongoing research into long-acting HIV therapies and efforts towards finding an HIV cure.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.